U.S. regulators accepted a label growth for Novo Nordisk’s weight problems drug Wegovy to tout its advantages for the center, a transfer that would increase demand and insurance coverage protection for the already extremely standard therapy.
The new label signifies that Wegovy can be utilized to scale back the chance of main coronary heart problems — together with coronary heart assault, stroke, or cardiovascular-related deaths — for individuals with obese or weight problems and present coronary heart illness, Novo mentioned in an announcement Friday.
The choice was primarily based on outcomes of a big, five-year trial that confirmed Wegovy reduce the chance of cardiovascular issues by 20% in that inhabitants. That is the primary time a weight reduction therapy has been accepted to additionally assist enhance coronary heart outcomes, the FDA said.
Get limitless entry to award-winning journalism and unique occasions.
Subscribe
